Primary Immunodeficiencies with Elevated IgE

International Reviews of Immunology

Volumn 35, Issue 1, 2016, Pages 39-56

  Mogensen, Trine H ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

atypical mycobacteriosis; chronic mucocutaneous candidiasis; DOCK8; herpes virus infections; hyper IgE syndrome; JAK STAT signaling; primary immunodeficiency; staphylococcus aureus; STAT3; TYK2

Indexed keywords

ALPHA INTERFERON; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIVIRUS AGENT; CORTICOSTEROID; IMIQUIMOD; IMMUNOGLOBULIN; IMMUNOGLOBULIN E; INTERLEUKIN 17; INTERLEUKIN 21 RECEPTOR; INTERLEUKIN 22; PROTEIN KINASE TYK2; STAT3 PROTEIN; ANTIINFECTIVE AGENT; CYTOKINE; DOCK8 PROTEIN, HUMAN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; PGM3 PROTEIN, HUMAN; PHOSPHOGLUCOMUTASE; STAT3 PROTEIN, HUMAN; TYK2 PROTEIN, HUMAN;

ANTIBIOTIC THERAPY; ANTIVIRAL THERAPY; ASTHMA; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DOCK8 IMMUNODEFICIENCY SYNDROME; ECZEMA; EOSINOPHILIA; HUMAN; HYPER IGE SYNDROME; IMMUNE DEFICIENCY; IMMUNOLOGY; LYMPHOCYTOPENIA; LYMPHOMA; MUCOCUTANEOUS CANDIDIASIS; MYCOSIS; OMENN SYNDROME; PATHOGENESIS; PGM3 DEFICIENCY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SEVERE COMBINED IMMUNODEFICIENCY; SKIN ABSCESS; SQUAMOUS CELL CARCINOMA; STAPHYLOCOCCUS INFECTION; T LYMPHOCYTE; VASCULITIS; BLOOD; DIFFERENTIAL DIAGNOSIS; GENETICS; JOB SYNDROME; METABOLISM; MUTATION; SIGNAL TRANSDUCTION;

ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; ANTIVIRAL AGENTS; B-LYMPHOCYTES; BONE MARROW TRANSPLANTATION; CYTOKINES; DIAGNOSIS, DIFFERENTIAL; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; IMMUNOGLOBULIN E; JOB SYNDROME; MUTATION; PHENOTYPE; PHOSPHOGLUCOMUTASE; SEVERE COMBINED IMMUNODEFICIENCY; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES; TYK2 KINASE;

EID: 84939479117     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2015.1027820     Document Type: Review

References (85)

1. Casanova JL, Abel L, Quintana-Murci L. Immunology taught by human genetics. Cold Spring Harb Symp Quant Biol 2013;78:157-172.
2. Ochs HD, Smith CIE, Puck JM. Primary immunodeficiencies: A molecular and genetic approach, 2nd ed. New York, NY: Oxford University Press; 2007.
3. Holland SM, DeLeo FR, Elloumi HZ, et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med 2007;357:1608-1619.
4. Minegishi Y, SaitoM, Tsuchiya S, et al. Dominant-negativemutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 2007;448:1058-1062.
5. Milner JD, Brenchley JM, Laurence A, et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008;452:773-776.
6. Engelhardt KR, McGhee S, Winkler S, et al. Large deletions and pointmutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome. J Allergy Clin Immunol 2009;124:1289-1302.
7. Zhang Q, Davis JC, Lamborn IT, et al. Combined immunodeficiency associated with DOCK8mutations. N Engl JMed 2009;361:2046-2055.
8. Zhang Y, Yu X, Ichikawa M, et al. Autosomal recessive phosphoglucomutase 3 (PGM3) mutations link glycosylation defects to atopy, immune deficiency, autoimmunity, and neurocognitive impairment. J Allergy Clin Immunol 2014;133:1400-1409.
9. Sassi A, Lazaroski S, Wu G, et al. Hypomorphic homozygous mutations in phosphoglucomutase 3 (PGM3) impair immunity and increase serum IgE levels. J Allergy Clin Immunol 2014;133:1410-1419.
10. Davis SD, Schaller J, Wedgwood RJ. Job's Syndrome. Recurrent, "cold, " staphylococcal abscesses. Lancet 1966;1:1013-1015.
11. Buckley RH, Wray BB, Belmaker EZ. Extreme hyperimmunoglobulinemia E and undue susceptibility to infection. Pediatrics 1972;49:59-70.
12. Sowerwine KJ, Holland SM, Freeman AF. Hyper-IgE syndrome update. Ann N Y Acad Sci 2012;1250:25-32.
13. Kindle G, Gathmann B, Grimbacher B. The use of databases in primary immunodeficiencies. Curr Opin Allergy Clin Immunol 2014;14(6):501-508.
14. Buckley RH, Wray BB, Belmaker EZ. Extreme hyperimmunoglobulinemia E and undue susceptibility to infection. Pediatrics 1972;49:59-70.
15. Siegel AM, Heimall J, Freeman AF, et al. A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory. Immunity 2011;35: 806-818.
16. Smithwick EM, Finelt M, Pahwa S, et al. Cranial synostosis in Job's syndrome. Lancet 1978;1:826.
17. O'Connell AC, Puck JM, Grimbacher B, et al. Delayed eruption of permanent teeth in hyperimmunoglobulinemia E recurrent infection syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;89:177-185.
18. Grimbacher B, Holland SM, Gallin JI, et al. Hyper-IgE syndrome with recurrent infections-an autosomal dominantmultisystem disorder. N Engl JMed 1999;340:692-702.
19. Freeman AF, Avila EM, Shaw PA, et al. Coronary artery abnormalities in hyper-IgE syndrome. J Clin Immunol 2011;31:338-345.
20. Freeman AF, Collura-Burke CJ, Patronas NJ, et al. Brain abnormalities in patients with hyperimmunoglobulin E syndrome. Pediatrics 2007;119:e1121-e1125.
21. Leonard GD, Posadas E, Herrmann PC, et al. Non-Hodgkin's lymphoma in Job's syndrome: A case report and literature review. Leuk Lymphoma 2004;45:2521-2525.
22. Holland SM, DeLeo FR, Elloumi HZ, et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med 2007;357:1608-1619.
23. Minegishi Y, Saito M, Tsuchiya S, et al. et al. Dominant-negativemutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 2007;448:1058-1062.
24. Renner ED, Rylaarsdam S, Anover-Sombke S, et al. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. J Allergy Clin Immunol 2008;122:181-187.
25. Mogensen TH, JakobsenMA, Larsen CS. Identification of a novel STAT3mutation in a patient with hyper-IgE syndrome. Scand J Infect Dis 2013;45:235-238.
26. Woellner C, Gertz EM, Schaffer AA, et al. Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome. J Allergy Clin Immunol 2010;125:424-432.
27. Tamassia N, Castellucci M, Rossato M, et al. Uncovering an IL-10-dependent NF-kappaB recruitment to the IL-1ra promoter that is impaired in STAT3 functionally defective patients. FASEB J 2010;24:1365-1375.
28. O'Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immunemediated disease. Immunity 2012;36:542-550.
29. Takeda K, Noguchi K, Shi W, et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci USA 1997;94:3801-3804.
30. Wang WB, Levy DE, Lee CK. STAT3 negatively regulates type I IFN-mediated antiviral response. J Immunol 2011;187:2578-2585.
31. Milner JD, Brenchley JM, Laurence A, et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008;452:773-776.
32. Puel A, Cypowyj S, Marodi L, et al. Inborn errors of human IL-17 immunity underlie chronicmucocutaneous candidiasis. Curr Opin Allergy Clin Immunol 2012;12:616-622.
33. Laan M, Cui ZH, Hoshino H, et al. Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J Immunol 1999;162:2347-2352.
34. Hill HR, Ochs HD, Quie PG, et al. Defect in neutrophil granulocyte chemotaxis in Job's syndrome of recurrent "cold" staphylococcal abscesses. Lancet 1974;2:617-619.
35. Buckley RH, Becker WG. Abnormalities in the regulation of human IgE synthesis. Immunol Rev 1978;41:288-314.
36. Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl JMed 2002;347:1151-1160.
37. Conti HR, Baker O, Freeman AF, et al. Newmechanism of oral immunity tomucosal candidiasis in hyper-IgE syndrome. Mucosal Immunol 2011;4:448-455.
38. Minegishi Y, Saito M, Nagasawa M, et al. Molecular explanation for the contradiction between systemic Th17 defect and localized bacterial infection in hyper-IgE syndrome. J Exp Med 2009;206:1291-1301.
39. Speckmann C, Enders A, Woellner C, et al. Reduced memory B cells in patients with hyper IgE syndrome. Clin Immunol 2008;129:448-454.
40. Avery DT, Deenick EK, Ma CS, et al. B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J ExpMed 2010;207:155-171.
41. Ozaki K, Spolski R, Feng CG, et al. A critical role for IL-21 in regulatingimmunoglobulin production. Science 2002;298:1630-1634.
42. AveryDT, Ma CS, Bryant VL, et al. STAT3 is required for IL-21-induced secretion of IgE fromhuman naive B cells. Blood 2008;112:1784-1793.
43. Kotlarz D, Zietara N, Uzel G, et al. Loss-of-function mutations in the IL-21 receptor gene cause a primary immunodeficiency syndrome. J ExpMed 2013;210:433-443.
44. Wesemann DR, Magee JM, Boboila C, et al. Immature B cells preferentially switch to IgE with increased direct SMU to Sepsilon recombination. J ExpMed 2011;208:2733-2746.
45. Saito M, Nagasawa M, Takada H, et al. Defective IL-10 signaling in hyper-IgE syndrome results in impaired generation of tolerogenic dendritic cells and induced regulatory T cells. J Exp Med 2011;208:235-249.
46. Panopoulos AD, Zhang L, Snow JW, et al. STAT3 governs distinct pathways in emergency granulopoiesis andmature neutrophils. Blood 2006;108:3682-3690.
47. Nieminen P, Morgan NV, Fenwick AL, et al. Inactivation of IL11 signaling causes craniosynostosis, delayed tooth eruption, and supernumerary teeth. Am J Hum Genet 2011;89:67-81.
48. Kida H, Mucenski ML, Thitoff AR, et al. GP130-STAT3 regulates epithelial cell migration and is required for repair of the bronchiolar epithelium. AmJ Pathol 2008;172:1542-1554.
49. Loeys BL, Schwarze U, Holm T, et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl JMed 2006;355:788-798.
50. Kovacic JC, Gupta R, Lee AC, et al. Stat3-dependent acute Rantes production in vascular smooth muscle cells modulates inflammation following arterial injury in mice. J Clin Invest 2010;120:303-314.
51. Zhang Z, Welte T, Troiano N, et al. Osteoporosiswith increased osteoclastogenesis in hematopoietic cell-specific STAT3-deficient mice. Biochem Biophys Res Commun 2005;328:800-807.
52. Okada S, Nakamura M, Katoh H, et al. Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after spinal cord injury. NatMed 2006;12:829-834.
53. Debnath B, Xu S, Neamati N. Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein. JMed Chem 2012;55:6645-6668.
54. Casanova JL, Holland SM, Notarangelo LD. Inborn errors of human JAKs and STATs. Immunity 2012;36:515-528.
55. Minegishi Y, Saito M, Morio T, et al. Human tyrosine kinase 2 deficiency reveals its requisite roles inmultiple cytokine signals involved in innate and acquired immunity. Immunity 2006;25:745-755.
56. Kilic SS, Hacimustafaoglu M, Boisson-Dupuis S, et al. A patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome. J Pediatr 2012;160:1055-1057.
57. Renner ED, Puck JM, Holland SM, et al. Autosomal recessive hyperimmunoglobulin E syndrome: A distinct disease entity. J Pediatr 2004;144:93-99.
58. Su HC, Jing H, Zhang Q. DOCK8 deficiency. Ann N Y Acad Sci 2011;1246:26-33.
59. Zhang Q, Davis JC, Dove CG, Su HC. Genetic, clinical, and laboratorymarkers for DOCK8 immunodeficiency syndrome. DisMarkers 2010;29:131-139.
60. Zhang Q, Su HC. Hyperimmunoglobulin E syndromes in pediatrics. Curr Opin Pediatr 2011;23:653-658.
61. Jabara HH, McDonald DR, Janssen E, et al. DOCK8 functions as an adaptor that links TLR-MyD88 signaling to B cell activation. Nat Immunol 2012;13:612-620.
62. Al KS, Keles S, Garcia-Lloret M, et al. Defects along the T(H)17 differentiation pathway underlie genetically distinct forms of the hyper-IgE syndrome. J Allergy Clin Immunol 2009;124:342-348.
63. Simon AR, Vikis HG, Stewart S, et al. Regulation of STAT3 by direct binding to the Rac1 GTPase. Science 2000;290:144-147.
64. Rael EL, Marshall RT, McClain JJ. The hyper-IgE syndromes: lessons in nature, frombench to bedside. World Allergy Organ J 2012;5:79-87.
65. DasoukiM, Okonkwo KC, Ray A, et al. Deficient T cell receptor excision circles (TRECs) in autosomal recessive hyper-IgE syndrome caused by DOCK8mutation: implications for pathogenesis and potential detection by newborn screening. Clin Immunol 2011;141:128-132.
66. Harada Y, Tanaka Y, Terasawa M, et al. DOCK8 is a Cdc42 activator critical for interstitial dendritic cell migration during immune responses. Blood 2012;119:4451-4461.
67. Su HC, Jing H, Zhang Q. DOCK8 deficiency. Ann N Y Acad Sci 2011;1246:26-33.
68. Jabara HH, McDonald DR, Janssen E, et al. DOCK8 functions as an adaptor that links TLR-MyD88 signaling to B cell activation. Nat Immunol 2012;13:612-620.
69. Yong PF, Freeman AF, Engelhardt KR, et al. An update on the hyper-IgE syndromes. Arthritis Res Ther 2012;14:228.
70. Randall KL, Lambe T, Goodnow CC, Cornall RJ. Theessential role of DOCK8 in humoral immunity. DisMarkers 2010;29:141-150.
71. Lambe T, CrawfordG, Johnson AL, et al. DOCK8 is essential for T-cell survival and themaintenance of CD8+ T-cell memory. Eur J Immunol 2011;41:3423-3435.
72. Alsum Z, Hawwari A, Alsmadi O, et al. Clinical, immunological and molecular characterization of DOCK8 and DOCK8-like deficient patients: single center experience of twenty-five patients. J Clin Immunol 2013;33:55-67.
73. Watford WT, O'Shea JJ. Human tyk2 kinase deficiency: Another primary immunodeficiency syndrome. Immunity 2006;25:695-697.
74. ShawMH, Boyartchuk V, Wong S, et al. A naturalmutation in the Tyk2 pseudokinasedomain underlies altered susceptibility of B10. Q/J mice to infection and autoimmunity. Proc Natl Acad Sci USA 2003;100:11594-11599.
75. Wolfe LA, Krasnewich D. Congenital disorders of glycosylation and intellectual disability. Dev Disabil Res Rev 2013;17:211-225.
76. Greig KT, Antonchuk J, Metcalf D, et al. Agm1/Pgm3-mediated sugar nucleotide synthesis is essential for hematopoiesis and development. Mol Cell Biol 2007;27:5849-5859.
77. Ozcan E, Notarangelo LD, Geha RS. Primary immune deficiencies with aberrant IgE production. J Allergy Clin Immunol 2008;122:1054-1062.
78. Antoniades K, Hatzistilianou M, Pitsavas G, et al. Co-existence of Dubowitz and hyper-IgE syndromes: A case report. Eur J Pediatr 1996;155:390-392.
79. Boeck A, Gfatter R, Braun F, Fritz B. Pentasomy X and hyper IgE syndrome: co-existence of two distinct genetic disorders. Eur J Pediatr 1999;158:723-726.
80. Boeck A, Kosan C, Ciznar P, Kunz J. Saethre-Chotzen syndromeand hyper IgE syndromein a patient with a novel 11 bp deletion of the TWIST gene. Am JMed Genet 2001;104:53-56.
81. Mandell GL, Bennett JE, Dolin R. Mandell, Douglas, and Bennett's principles and practice of infectious diseases, 7th ed. London: Churchill Livingstone; 2010.
82. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009;228:273-287.
83. Goussetis E, Peristeri I, Kitra V, et al. Successful long-term immunologic reconstitution by allogeneic hematopoietic stem cell transplantation cures patients with autosomal dominant hyper-IgE syndrome. J Allergy Clin Immunol 2010;126:392-394.
84. Gatz SA, Benninghoff U, Schutz C, et al. Curative treatment of autosomal-recessive hyper-IgE syndrome by hematopoietic cell transplantation. BoneMarrow Transplant 2011;46:552-556.
85. Barlogis V, Galambrun C, Chambost H, et al. Successful allogeneic hematopoietic stem cell transplantation for DOCK8 deficiency. J Allergy Clin Immunol 2011;128:420-422.